Potential Role of Hesperidin in Improving Experimental Pulmonary Arterial Hypertension in Rats via Modulation of the NF ‐ κB Pathway
Authors:
- 20 March 2025
- journal article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 105 (3) , e70068
Abstract
This study was designed to evaluate the therapeutic effects of hesperidin, an anti‐inflammatory compound, on pulmonary arterial hypertension (PAH). A PAH rat model was established using monocrotaline (MCT, 60 mg/kg). Next, the experimental animals were assigned into the following four groups ( n = 6 per group): Control group, MCT group, MCT + H20 group (20 mg/kg hesperidin), and MCT + H40 group (40 mg/kg hesperidin). According to the experimental outcomes, the PAH rat model was built successfully. In PAH animals, hesperidin significantly reduced right ventricular systolic pressure, Fulton index, and mean pulmonary arterial pressure. Concurrently, it improved pulmonary artery velocity‐time integral and acceleration time, as well as alleviated pulmonary artery and right ventricular remodeling. On a molecular level, hesperidin inhibited the expression of vascular endothelial‐cadherin, alpha‐smooth muscle actin, matrix metalloproteinase‐9, and transforming growth factor beta. Also, hesperidin downregulated pro‐inflammatory cytokines such as interleukin (IL)‐6, IL‐1β, IL‐18, chemokine C‐C motif ligand 2, and C‐X‐C motif chemokine ligand 1 levels, and reduced the number of CD68+ cells in tissue samples. Further analysis revealed that hesperidin could inhibit the activation of p‐IκB‐α and p‐p65 in samples induced by MCT. Collectively, these findings suggest that hesperidin may inhibit inflammation through the NF‐κB pathway, thereby improving experimental PAH in rats induced by MCT.Keywords
This publication has 37 references indexed in Scilit:
- Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial HypertensionInternational Journal of Pharmaceutics, 2022
- Effects in vitro and in vivo of hesperidin administration in an experimental model of acute lung inflammationFree Radical Biology and Medicine, 2022
- The soluble guanylate cyclase stimulator, 1-nitro-2-phenylethane, reverses monocrotaline-induced pulmonary arterial hypertension in ratsLife Sciences, 2021
- TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertensionDrug Discovery Today, 2019
- CCL21 as a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic SclerosisArthritis & Rheumatology, 2018
- Blood pressure lowering and anti‐inflammatory effects of hesperidin in type 2 diabetes; a randomized double‐blind controlled clinical trialPhytotherapy Research, 2018
- CTRP9 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation, apoptosis and migration via TGF-β1/ERK1/2 signaling pathwayBiochemical and Biophysical Research Communications, 2017
- Targeting Vascular Remodeling to Treat Pulmonary Arterial HypertensionTrends in Molecular Medicine, 2017
- Signaling via the NFκB systemWIREs Mechanisms of Disease, 2016
- VE-Cadherin and Endothelial Adherens Junctions: Active Guardians of Vascular IntegrityDevelopmental Cell, 2013